Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib.
Saved in:
| Title: | Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib. |
|---|---|
| Authors: | Qin, Ya-Zhen1 (AUTHOR), Jiang, Qian1 (AUTHOR), Lai, Yue-Yun1 (AUTHOR), Jiang, Hao1 (AUTHOR), Shi, Hong-Xia1 (AUTHOR), Zhao, Xiao-Su1 (AUTHOR), Liu, Yan-Rong1 (AUTHOR), Huang, Xiao-Jun1,2 (AUTHOR) xjhrm@medmail.com.cn |
| Source: | Leukemia & Lymphoma. Jun2017, Vol. 58 Issue 6, p1384-1393. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 10428194 |
|---|---|
| DOI: | 10.1080/10428194.2016.1239260 |
